Spots Global Cancer Trial Database for The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China
Official Title: The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China
Study ID: NCT04228393
Conditions
Study Description
Brief Summary: The purpose of this study was to assess the efficacy and safety of individualized treatment of 6-mercaptopurine (6-MP) in Chinese children with acute lymphoblastic leukemia, and to investigate the dose-concentration-response (DER) relationship between thiopurine metabolites and adverse events. The individualized administration of 6-MP was established in Chinese children with acute lymphoblastic leukemia.
Detailed Description: To inflict minimal pain on the child contributing blood samples, opportunistic sampling design was chosen to collect pharmacokinetic samples.
Eligibility
Minimum Age: 1 Year
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tanjin, Tianjin, China
Contact Details
Name: Wei Zhao, Ph.D
Affiliation: Shandong University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
